Jeffrey Su, Ph.D., has been named vice president of bioanalytical development at Cytovance Biologics. Dr. Su will head up the bioanalytical development laboratory supporting existing and new client needs. This lab is part of the ongoing strategic expansion of the facilities to add scientific capabilities and the 1,000L Microbial, 1,000L and 5,000L Mammalian process train capacity. “I see this addition as a key placement to meet the needs of our expansion,” said Darren Head, president chief executive officer of Cytovance.

Dr. Su has more than 17 years experience in the pharmaceutical/biotech industry. He has extensive experience in R&D, Process development, cGMP manufacturing, analytical development and quality systems, as well as regulatory affairs. He has successfully managed projects involving partners in the U.S., Asia, Canada and Europe.

Before joining Cytovance, Dr. Su was the vice president of operation and product development at Femta Pharmaceuticals in San Diego, CA. Prior to his tenure at Femta, he served as the deputy director and platform leader for formulation at Sanofi Pasteur, the senior director for manufacturing and control at CancerVax Inc., and other roles at Dow Chemical, Tanox, Pharming Healthcare, Medarex, Human Genome Sciences and Roche.

The bioanalytical development lab will be housed in Cytovance’s multi-product cGMP production facility in Oklahoma City, OK. The 44,000-sq.-ft. facility meets the latest international regulatory standards and is custom-designed for efficient and cost-effective production, according to the company.